Woori Bank's IO affiliation and share swap details disclosed by OSR Holdings
In a significant move towards advancing biomedical and wellness innovation, OSR Holdings, Inc. has announced a strategic update regarding a Term Sheet with Woori IO Co., Ltd., a South Korean medical device company pioneering noninvasive glucose monitoring technology.
Woori IO Co., Ltd. has completed a proof-of-concept study at Korea University Hospital and is now preparing for a larger confirmatory study for regulatory approval in Korea. This makes WORIO one of the rare companies globally to have both a working prototype and a regulatory engagement plan for noninvasive glucose monitoring, a field in which no company has received regulatory approval as of the current date.
Upon completion of the transaction, Woori IO Co., Ltd. will become a wholly owned subsidiary of OSR Holdings Co., Ltd., a Korean affiliate of OSRH. The acquisition is intended to position OSRH as an early acquirer of WORIO ahead of full commercialization of its noninvasive glucose monitoring technology.
The technology leverages near-infrared spectroscopy (NIRS) to deliver accurate, needle-free glucose measurement, making it well suited for integration into wearable devices such as smartwatches. This aligns with WORIO's selection for Samsung Electronics' innovative startup program, C-Lab Outside, in Q1 2025.
The projected timeline indicates that after completing the confirmatory trials and gaining regulatory approval, WORIO’s technology could reach commercial maturity in the near future, potentially positioning OSR Holdings as a key player in the expanding noninvasive glucose monitoring market projected to exceed $40 billion by 2030.
The acquisition also offers benefits to WORIO shareholders. They will receive newly issued OSRK shares, with a conditional right to exchange those shares for OSRH common stock if OSRH's share price reaches $10.00 or more within three years from the signing of the Term Sheet. This $10 OSRH share condition is intended as a performance-aligned incentive, reflecting the long-term confidence in OSRH's growth potential.
If OSRH's share price does not meet the $10.00 threshold within three years, the conversion will not occur, and WORIO shareholders will remain equity holders in the privately held OSRK entity.
OSRH looks forward to further engaging with investors as this transaction develops. The company will continue confirmatory legal, financial, and technical due diligence during a 6-month exclusivity period set forth in the Term Sheet.
The non-invasive glucose monitoring technology developed by WORIO could generate valuable novel datasets for various research areas, such as metabolic syndrome, cancer relapse, exercise benefits, pre- and probiotics, and elite athletic performance.
[1]: Source for the projected market growth of noninvasive glucose monitoring market [3]: Source for WORIO's selection for Samsung Electronics' innovative startup program [5]: Source for the details of the acquisition and the timeline of events
Science and technology intersect in the strategic alliance between OSR Holdings and Woori IO Co., Ltd., as the South Korean medical device company develops noninvasive glucose monitoring technology that may revolutionize health-and-wellness sectors, such as metabolic syndrome research, cancer relapse studies, and elite athletic performance. [1][3]
